Glioma Therapy

Selective estrogen receptor modulators induce glioma cell apoptosis

Published in Proteomics Weekly, March 7th, 2005

Selective estrogen receptor modulators (SERMs) induce apoptosis in glioma cells in vivo.

The SERM tamoxifen "is widely used in the treatment of estrogen receptor (ER)-expressing breast cancer," oncologists in the United States explained. "It has previously been shown that high-dose tamoxifen has cytotoxic activity against glioma cells, but whether this effect is drug-specific or represents a general property of SERMs is unknown."

In a recent study, A.M. Hui and coauthors at the National Cancer Institute found that "tamoxifen and CC-8490, a novel benzopyranone with SERM activity, induce glioma cell apoptosis in a dose- and time-dependent...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Proteomics Weekly

Source: Proteomics Weekly (2005-03-07)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry